POPULARITY
5 episodes with disease modeling
4 episodes with disease modeling
5 episodes with disease modeling
5 episodes with disease modeling
5 episodes with disease modeling
2 episodes with disease modeling
5 episodes with disease modeling
5 episodes with disease modeling
5 episodes with disease modeling
In this episode of the Scope of Things, host Deborah Borfitz brings you the latest news on AI-recommended precision dosing, organoid drug testing aiding treatment selection for bowel cancer, an AI tool for stratifying lung cancer patients, using HIV drugs to treat Alzheimer's disease, and the potential value of magic mushrooms to remedy the mood symptoms of Parkinson's. Blythe Adamson, international head of outcomes research and evidence generation at Flatiron Health, also joins in to discuss groundbreaking work harmonizing patient-level real-world data across four countries to enable multinational oncology research. News Roundup CURATE.AI platform Article in Clinical Research News Study in npj Precision Oncology FORECAST-2 clinical trial News on the Walter and Eliza Hall Institute website AI tool for sorting cancer patients Study in Nature Communications HIV drugs for Alzheimer's protection Study in Alzheimer's & Dementia “Magic mushrooms” for Parkinson's disease Study in Neuropsychopharmacology Guest Blythe Adamson, Ph.D., international head of outcomes research and evidence generation at Flatiron Health Flatiron Health enabling multinational oncology researh – article in Bio-IT World Subscribe to the podcast on Apple Podcasts and leave a review to support the show. Join us at Scope Europe on October 14-15 in Barcelona - use code SOT10 for an additional 10% discount. GUEST BIO Blythe Adamson, PhD, MPH, Head of Outcomes Research and Evidence Generation, International at Flatiron Health & Founder of Infectious Economics Dr. Blythe Adamson is the head of international outcomes research and evidence generation at Flatiron Health. As a visionary senior leader at Flatiron Health, her team pioneered deep learning language models for extraction of clinical details from EHR documents, breaking the limits of what was possible for humans to do alone. Learning from the experience of millions of patients with cancer, they generate evidence of treatment effectiveness and value used by governments around the world. Dr. Adamson co-invented a patented clinical decision-support tool, enabled by machine learning, that is used by cancer clinics to benefit patients. She holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention. Dr. Adamson has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, the NIAID HIV Vaccine Trials Network, and Flatiron Health. The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.
Send us a textDr. Blythe Adamson, PhD, MPH ( https://www.blytheadamson.com/ ) is Head of Outcomes Research and Evidence Generation at Flatiron Health ( https://flatiron.com/ ), where her work has been focused on developing deep learning language models for extraction of clinical details from EHR documents, ultimately learning from the experience of millions of patients with cancer, and generating evidence of treatment effectiveness and value used by governments around the world. Dr. Adamson is a scientist, epidemiologist and economist ( https://scholar.google.com/citations?user=jAflVcUAAAAJ&hl=en ), who co-invented a patented clinical decision-support tool, enabled by machine learning, that is used by cancer clinics to benefit patients.Formerly a lead data scientist in the West Wing of The White House, Dr. Adamson has been involved in advising public and private institutions including professional sports leagues, the entertainment industry, retailers, manufacturers, and more.Dr. Adamson founded the company Infectious Economics ( https://www.infectiouseconomics.com/ ), with a focus to provide thought leadership to policy makers and industry leaders on cost-effective strategies to prevent the transmission of viruses.Dr. Adamson holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention, doing her Master of Public Health in Epidemiology, and Ph.D. in Pharmaceutical Outcomes Research and Policy, at the University of Washington, where she still lectures as an Affiliate Assistant Professor ( https://sop.washington.edu/people/blythe-adamson/ ).Dr. Adamson has also held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling and the NIAID HIV Vaccine Trials Network and is a Board Member of NBA-funded SalivaDirect lab at Yale.#BlytheAdamson #FlatironHealth #EHR #Oncology #Cancer #HIV #InfectiousEconomics #RWE #RealWorldEvidence #ElectronicHealthRecords #RealWorldData #ClinicalDecisions #HealthPolicies #LargeLanguageModels #LLM #AI #ArtificialIntelligence #MachineLearning #ML #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
What do crime waves, contagious diseases, and social trends have in common? Neil deGrasse Tyson and co-host Chuck Nice welcome best-selling author Malcolm Gladwell to explore the hidden forces that drive human behavior.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/revenge-of-the-tipping-point-with-malcolm-gladwell/Thanks to our Patrons Matt Silkowski, Dylan moffitt, Grahan Rossiter, FunThings2See, Anthony Sipple, Micheal Kemp, Alexandria French, Ali Jasemi, Nick Charles, Christopher Scott, Graham Jones, Richarad Negus, Win Lương, Paul Durae Duncan, Ian Diaz, Micheal Kroes, Adam Bodenhamer, Chris, foo red, Micheal Rivera, Charles Stanley-Grey, Samuel Andrews, Damian Cartwright, Maliha Khan, Carleton Chang, Jay Holmes Jr. , Mike McKinney, Justin Zarsky, ImJustBeingLazy, Nicholas Elias, Ruth, Brian Toms, Zach Stein, Melanie, Noah, and Philip Taylor for supporting us this week. Subscribe to SiriusXM Podcasts+ on Apple Podcasts to listen to new episodes ad-free and a whole week early.
Learn about advancements in precision medicine, particularly the role of AI, stem cell research, and gene therapy. Experts highlight AI's potential in personalized treatments, diagnostics, and patient care. Key topics include RNA targeting therapies, base editing for gene mutations, and using stem cells for disease modeling and regeneration. AI's contribution to enhancing healthcare efficiency and decision-making is also explored, emphasizing its role in personalized medicine through large data sets. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39981]
Learn about advancements in precision medicine, particularly the role of AI, stem cell research, and gene therapy. Experts highlight AI's potential in personalized treatments, diagnostics, and patient care. Key topics include RNA targeting therapies, base editing for gene mutations, and using stem cells for disease modeling and regeneration. AI's contribution to enhancing healthcare efficiency and decision-making is also explored, emphasizing its role in personalized medicine through large data sets. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39981]
Learn about advancements in precision medicine, particularly the role of AI, stem cell research, and gene therapy. Experts highlight AI's potential in personalized treatments, diagnostics, and patient care. Key topics include RNA targeting therapies, base editing for gene mutations, and using stem cells for disease modeling and regeneration. AI's contribution to enhancing healthcare efficiency and decision-making is also explored, emphasizing its role in personalized medicine through large data sets. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39981]
Learn about advancements in precision medicine, particularly the role of AI, stem cell research, and gene therapy. Experts highlight AI's potential in personalized treatments, diagnostics, and patient care. Key topics include RNA targeting therapies, base editing for gene mutations, and using stem cells for disease modeling and regeneration. AI's contribution to enhancing healthcare efficiency and decision-making is also explored, emphasizing its role in personalized medicine through large data sets. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39981]
Proudly sponsored by PyMC Labs, the Bayesian Consultancy. Book a call, or get in touch!My Intuitive Bayes Online Courses1:1 Mentorship with meOur theme music is « Good Bayesian », by Baba Brinkman (feat MC Lars and Mega Ran). Check out his awesome work!Visit our Patreon page to unlock exclusive Bayesian swag ;)-------------------------Love the insights from this episode? Make sure you never miss a beat with Chatpods! Whether you're commuting, working out, or just on the go, Chatpods lets you capture and summarize key takeaways effortlessly.Save time, stay organized, and keep your thoughts at your fingertips.Download Chatpods directly from App Store or Google Play and use it to listen to this podcast today!https://www.chatpods.com/?fr=LearningBayesianStatistics-------------------------Takeaways:Epidemiology focuses on health at various scales, while biology often looks at micro-level details.Bayesian statistics helps connect models to data and quantify uncertainty.Recent advancements in data collection have improved the quality of epidemiological research.Collaboration between domain experts and statisticians is essential for effective research.The COVID-19 pandemic has led to increased data availability and international cooperation.Modeling infectious diseases requires understanding complex dynamics and statistical methods.Challenges in coding and communication between disciplines can hinder progress.Innovations in machine learning and neural networks are shaping the future of epidemiology.The importance of understanding the context and limitations of data in research. Chapters:00:00 Introduction to Bayesian Statistics and Epidemiology03:35 Guest Backgrounds and Their Journey10:04 Understanding Computational Biology vs. Epidemiology16:11 The Role of Bayesian Statistics in Epidemiology21:40 Recent Projects and Applications in Epidemiology31:30...
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Giorgia Quadrato, Ph.D., explores cerebral organoids as models for neural development and disease research. Using live calcium imaging, Quadrato observes increased neuronal coordination attributed to inhibitory neurons, validated through pharmacological and genetic methods. Quadrato contrasts their organoid generation protocol with previous methods, emphasizing complex patterning, long-term cultures, and co-culture with mouse brain cells for improved physiological relevance. Microfluidics are utilized for enhanced oxygenation and physiological conditions. Future efforts focus on incorporating microglial cells for synaptic pruning studies and overcoming challenges in cryopreservation. Overall, the research aims to advance understanding of neural mechanisms and diseases, enhancing organoid fidelity for biomedical applications. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39456]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Benjamin Freedman, Ph.D., delves into the creation and functionality of kidney organoids. He discusses their focus on filtration over hormone functions, and answer intriguing questions about urine characterization and the necessity of organoid structures. Freedman explores the use of scaffolds for implants and ponder the philosophical implications of off-target cells in organoids, questioning whether these cells are a natural part of organ development. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39455]
Dylan George, director of the CDC's Center for Forecasting and Outbreak Analytics, explains how the new public-private collaboration InsightNet is using advanced analytics and biosurveillance to respond to disease outbreaks and prevent future pandemics.
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Hans Clevers, M.D., Ph.D., shares his research at the intersection of medicine and biology. Clevers discusses revolutionary advances in personalized medicine, where patient-specific treatments can be developed by studying small samples of patients' tissues. He explores the role of specialized cells known as "best for cells" in gastrointestinal health, shedding light on how they may help fight infections. Additionally, he highlights how mini-organs, or organoids, grown in the lab help us understand complex cellular functions and diseases. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39066]
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.27.530330v1?rss=1 Authors: Gentili, H. G., Pignataro, M. F., Olmos, J., Pavan, M. F., Ibanez, L. I., Santos, J., Velazquez, F. Abstract: Here we present the development of a new model system for Friedreichs Ataxia (FA) using D. discoideum (Dd). FA is a rare disease caused by disfunction of frataxin (FXN), a protein involved in Fe-S cluster assembly machinery. We firstly investigated the conservation of function between human and D. discoideum. In this work we show that DdFXN can substitute the human version in the interaction and activation of Fe-S assembly supercomplex. DdFXN can in vitro displace HsFXN in competition assays and also it can activate cysteine desulfurase activity in the context of human Fe-S assembly supercomplex. We then manage to edit fxn locus and isolated clone 8, a defective mutant with undetectable levels of frataxin. Clone 8 presents landmarks of frataxin deficiency such as decrease in Fe-S cluster dependent enzymatic functions, growth rate reduction and increase sensitivity to oxidative stress. Besides these phenotypes, shared with other FA models, clone 8 presents defects in the multicellular developmental program induced by starvation in this protist. We then assessed the rescuing capacity of DdFXN G122V, a version that mimics a human variant presented in some FA patients. While expression of DdFXN G122V rescues growth and enzymatic activities defects as well as DdFXN does, multicellular development defects were only partially rescued. This work opens the door to develop drug or treatment screenings that would help to design, and/or evaluate therapeutical strategies. Besides this biological model offers a wide range of possibilities to easily explore diverse phenotypes in FA. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
Thomas C. Südhof, M.D., Stanford University, discusses facets of the fundamental cell biology of ApoE and APP analyzed in stem cell-derived human neurons. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38405]
The National Security Science podcast is a spin-off of National Security Science magazine at Los Alamos National Laboratory. We bring you stories that show how innovative science and engineering are the key to keeping America safe. Or, as we like to say, better science equals better security. LA-UR-22-28585
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
Thorold Theunissen, Ph.D., of the Washington University School of Medicine in St. Louis shares his work using naive stem cells to model trophoblast development, Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37674]
This conversation explores the impact some suggestions and questions that arose at Liver Connect might have on data modeling. Roger Green starts by mentioning that the Liver Connect panels felt that waist circumference measurement might be a better treatment/diagnostic metric than BMI, since it reflects both fat distribution within the body and region of the world. The group generally agreed that while waist circumference has value in diagnosing and treating individual patients, it's relative scarcity of data and inconsistent administration from one practitioner to another (key question: exactly how consistent in the definition of "waist"?) made it a weaker metric than other obesity measures for data modeling.From there, Alina Allen raised the issue of increased alcohol use and its impact on obesity (not yet measured, but likely to be a serious trend over time with negative impact on longevity and quality of life). During this conversation, the group also explores the value of regressing fibrosis levels vs. simply halting progression (thought: goals should vary based on patient age, fibrosis level and co-morbidities). Finally, the conversation turns to the idea of "fast progressors," with Alina and Jörn Schattenberg stating that slow progressors should be the research priority because they are so much more common. Alina suggests that what we call ""fast progressors" might in fact simply be people diagnosed late in the course of disease. As Chris notes, the overall pattern of disease, with its period of dormancy and spontaneous regression, makes this issue a challenge to model. The final comment comes from Roger, who points out that patients during fast progression or rapid decline are the most attractive patient targets economically, since per capita spend will be higher and will continue to increase in later stages of disease. However, he adds, we will need to track patients far more frequently than we do now to confirm or disprove any of these hypotheses about the nature of fast-progressing disease and the proportion of patients who are actual fast progressors.This conversation is sponsored by Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.
This conversation starts by focusing on issues related to diagnostic testing and what we attempt to detect or prove with each test. It starts with Roger Green noting the challenge of widespread population testing for fast progressors: the easy, inexpensive test for widespread 1st-line population testing is FIB-4, but FIB-4's lack of positive predictive value makes it a poor test for assessing this question, besides which, as Alina Allen notes, FIB-4 will increase with age.Chris Estes comments that modeling costs of a given approach must not only take into account the actual cost of an intervention (a drug, or surgery), but also the costs of testing, false positives, failed therapies and everything else that is part of patient diagnosis, treatment and monitoring. This leads into a brief detour on expected rates of adherence to pharmacotherapy for different types of medications.The final portion of the main episode explores how costs are likely to change over time and the value of interventions like a sugar tax of soft-drink cup size restriction. This section includes some specific modeling challenges coupled with a general recognition that prevention is less expensive in the long-run than treatment but more difficult to fund and support in the short run. In the end, the group agrees on the need to keep collecting data and maintain a holistic perspective on NAFLD and NASH in the overall context of metabolic disease. As Chris points out, the economic effects on NASH of an effort to reduce Type 2 Diabetes are likely to be extremely powerful.This conversation is sponsored by Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.
This conversation starts with Chris Estes describing the processes he and his colleagues at the Center for Disease Analysis Foundation have used to build a disease model for NAFLD and NASH prevalence in 15 countries. Chris discusses some of the unique challenges that modeling NASH presents. Among other items, these include (a) spontaneous regression of disease; (b) "excess" mortality (mortality not from liver disease where NASH is a contributing factor); and (c) interplay of demographics (gender, age, race, etc.) and co-morbidities (most notably Type 2 diabetes) with disease.When Chris ends his initial comments, Jörn Schattenberg asks about the viability of using obesity as the anchor for increasing prevalence estimates instead of diabetes, noting the varying definitions of BMI across countries. Chris notes that obesity is imperfect but adds that we have robust, stable, long-term obesity data bases in most countries, whereas diabetes estimates are newer and many people with diabetes to not recognize they have the disease.The last element in this conversation starts with Alina Allen noting that for clinical trial development, researchers test patients with a range of diagnostics. As a result, they do not need to develop estimates based on (or even linked directly to) obesity or diabetes. Alina asks what models can tell us that can help bring down high placebo rates in double-blinded, placebo-controlled clinical trials. Chris mentions meta analyses as recently as seven years ago that exhibited negative disease progression over time and adds that any assessment of F3 (or even F2) fibrosis is affected by concomitant disease.This conversation is sponsored by Resoundant Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.
This conversation starts with Chris Estes describing the processes he and his colleagues at the Center for Disease Analysis Foundation have used to build a disease model for NAFLD and NASH prevalence in 15 countries. Chris discusses some of the unique challenges that modeling NASH presents. Among other items, these include (a) spontaneous regression of disease; (b) "excess" mortality (mortality not from liver disease where NASH is a contributing factor); and (c) interplay of demographics (gender, age, race, etc.) and co-morbidities (most notably Type 2 diabetes) with disease.When Chris ends his initial comments, Jörn Schattenberg asks about the viability of using obesity as the anchor for increasing prevalence estimates instead of diabetes, noting the varying definitions of BMI across countries. Chris notes that obesity is imperfect but adds that we have robust, stable, long-term obesity data bases in most countries, whereas diabetes estimates are newer and many people with diabetes to not recognize they have the disease.The last element in this conversation starts with Alina Allen noting that for clinical trial development, researchers test patients with a range of diagnostics. As a result, they do not need to develop estimates based on (or even linked directly to) obesity or diabetes. Alina asks what models can tell us that can help bring down high placebo rates in double-blinded, placebo-controlled clinical trials. Chris mentions meta analyses as recently as seven years ago that exhibited negative disease progression over time and adds that any assessment of F3 (or even F2) fibrosis is affected by concomitant disease.This conversation is sponsored by Resoundant Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.
In Episode 13, we explored ways that data modeling can inform a deeper understanding of the value of community and primary care VCTE screening for NAFLD and NASH. This week, we ask Chris Estes, lead modeler at the Center for Disease Analysis Foundation, what guidance data modeling can provide about diagnostic and drug development.The episode is a cross between a discussion and an interview-type program. It starts with Chris explaining how he derives models, which variables he selects as proxy measures, why he chooses those, and where shortcomings exist in the data that is available for him to use in populating models. For much of the rest, the other panelists -- Alina Allen, Louise Campbell, Jörn Schattenberg and Roger Green -- either ask questions about how Chris's models work or what we can learn from them, and Chris answers. Beyond that, panelists share their own observations based on research and patient treatment experiences and Chris responds. The group covers a virtual shopping list of topics, including: underreported and misreported diseases; which proxies are more reliable when modeling disease (and which are less so); gaps in current data; positives, negatives and challenges in using obesity as the proxy variable for NAFLD instead of diabetes; the case for treating F2 agents with drugs when they become available; countries most at risk in the coming global NASH pandemic; the need to forecast pediatric NAFLD and NASH better; impact of alcohol consumption on NAFLD or NASH patients; and the situations where regressing fibrosis is pivotal vs. others where simply stopping progression might be a sufficient goal. In the end, this conversation offers a better understanding of how complex modeling is and how remarkable that people like Chris produce results that bear up so well over time.After the episode, keep listening for an "extra-sode," originally recorded on January 27, 2022, focusing on the practical value and uses of MRE in day-to-day practice. In addition to Louise Campbell and Roger Green, the panel for this extra-sode includes Stephen Harrison, Mazen Noureddin, Kay Pepin from Mayo Clinic and Resoundant, and Scott Reeder from the University of Wisconsin. This discussion, which appears as stand-alone conversation S3 E16.4, addresses the uses of MRE in community settings and the unique benefits MRE can bring as a standalone test and combined with MRI-PDFF in a test/reporting structure known as an hepatogram.This episode is sponsored by Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.
Dr. Machado talks about the pieces that are still missing and that could help them discover the diseases' routes. How do you think we could improve this data? *Watch the full episode here: https://www.swinecampus.com/blog ------------- The Swine it Podcast Show is trusted and supported by innovative companies like: - EveryPig (http://www.everypig.com/swineit/) - Zinpro (https://zinpro.com/) - Gestal (http://jygatech.com/) - AB Vista (https://www.abvista.com/) - Adisseo (http://www.adisseo.com/) - Genesus (https://www.genesus.com/) - Evonik (https://animal-nutrition.evonik.com/en/species/swine/) Give us a Rating & Review - http://getpodcast.reviews/id/1460280128
Disease prevention is a very important aspect of successful swine management but sometimes, no matter how good your biosecurity is, diseases find a way to infect the herd. This is why it is helpful to have effective plans in place to minimize the damage done. In today's talk Dr. Greiner, Dr. Gustavo Machado discusses how swine disease models work, what they will look like in the future, and how they can be effective to prepare for diseases such as ASF infecting our swine herds. "
Tigist (Tiggy) Menkir is a PhD student working with Dr. Caroline Buckee at the Center for Communicable Disease Dynamics housed within the Harvard T.H. Chan School of Public Health. She did her undergraduate training at Princeton University where she received her BA in Ecology and Evolutionary Biology with minors in Global Health and Health Policy and French Language in Culture. She studies infectious disease epidemiology and utilizes machine learning-based methods, spatial statistics, and traditional dynamic models for infectious disease surveillance, with a focus on data-limited settings and marginalized populations. Enjoy! --- Send in a voice message: https://podcasters.spotify.com/pod/show/fromwheredoesitstem/message
The Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer's and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the future of neurodegenerative research.
Why are 3D cell cultures so exciting? What IS the difference between a 2D and 3D cell culture? Experts from Corning; Audrey Bergeron, Claire (Linyu) Zhang, and Alejandro Montoya joined Marshall to explain the new applications of 3D cell cultures and what considerations need to be taken into account when working within these new models. If you are looking to transition to using 3D cell cultures, this episode outlines exactly what tools and training you will need to do so. Corning is the sponsor for the SLAS Technology Special Collection: Emerging Trends in 3D Cell Culture: High-Throughput Screening, Disease Modeling and Translational MedicineFor additional resources from Corning: 2021 Virtual 3D Cell Culture Summit – Watch On Demand3D Cell Culture Models e-Book Bundle Download Corning Solutions for 3D Cell Culture Registration is now open for the 2022 AI Data Pipelines for Life Sciences Symposium in Seattle, WA, September 26-27.This two-day symposium will allow participants to explore how AI data pipelines are integrated into the life sciences. Attendees will learn about MLOPS, applications, techniques, and architectures of data and their uses in the life sciences. The SLAS 2022 Bio Entrepreneurship Symposium will allow emerging bio entrepreneurs, start-up companies, academics and those considering bio-entrepreneurship to explore the start-up ecosystem. Register by visiting: https://www.slas.org/events-calendar/slas-2022-bio-entrepreneurship-symposium/attend/register/
Giovanni Sorrentino, Head of Molecular Liver Pathophysiology Unit Department of Life Sciences – University of Trieste Trieste, ITALY speaks on "New avenues in disease modeling and regenerative medicine of the enterohepatic system".
In his third talk, Clevers describes how organoids can guide our understanding of disease progression in cancer. In addition, using Cystic Fibrosis and cancer as examples, Clevers shows how organoids can be used to predict therapeutic outcome in patients.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.11.246371v1?rss=1 Authors: DING, B., Tang, Y., Ma, S., Akter, M., Liu, M.-L., Zang, T., Zhang, C.-L. Abstract: DYT1 dystonia is a hereditary neurological disease caused by a heterozygous mutation in torsin A (TOR1A). While animal models provide insights into disease mechanisms, significant species-dependent differences exist since mice with the identical heterozygous mutation fail to show pathology. Here, we model DYT1 by using human patient-derived motor neurons. These neurons with the heterozygous TOR1A mutation show markedly thickened nuclear lamina, disrupted nuclear morphology, and impaired nucleocytoplasmic transport, whereas they lack the perinuclear blebs that are often observed in animal models. Importantly, we further uncover that the nuclear lamina protein LMNB1 is specifically dysregulated in expression and subcellular localization. LMNB1 downregulation can largely ameliorate all the cellular defects in DYT1 motor neurons. These results reveal the value of disease modeling with human neurons and provide novel molecular mechanisms underlying DYT1 dystonia and potentially other neurological diseases with impaired nucleocytoplasmic transport. Copy rights belong to original authors. Visit the link for more info
Marc Lipsitch, Professor in the Departments of Epidemiology and Immunology and Infectious Diseases at Harvard University, and Director of the Center for Communicable Diseases and Dynamics joins hosts Drs. Dylan George and Caitlin Rivers as they consider data analytics, public health interventions, disease modeling, and the need for the public health community to be at the fore to help implement, design, and execute strategies to manage the COVID-19 response. References: Center for Communicable Disease Dynamics
Modeling is vital to understanding disease spread and optimal interventions. In this episode of the B.Next Outbreak Analytics & Forecasting series, Dr. Marita Zimmermann, Affiliate Assistant Professor and Research Economist at the Institute for Disease Modeling, discusses with Dr. Dylan George the need for modeling and how it's used to understand which people are at risk for COVID-19 and determine public health interventions to minimize their risk. References: Institute for Disease Modeling COVID-19 Reports
In this episode of the B.Next Outbreak Analytics & Forecasting series, Drs. Dylan George and Caitlin Rivers are joined by Dr. Nick Reich, one of the leading researchers who is building operational forecasting capabilities in collaboration with public health agencies. Listen in as they discuss the need for better quantity and quality data to have more high-resolution, real-time data to enable better modeling and guide response efforts, and the development of the CDC COVID-19 Forecasting Hub. References: COVID-19 Forecast Hub Reich Lab Technology to advance infectious disease forecasting for outbreak management
Episode two of the B.Next Outbreak Analytics & Forecasting series features Dr. Dylan George discussing simulated forecasting in infectious disease with Dr. Jeff Shaman, professor at Columbia University and director of the Climate and Health program at the Mailman School of Public Health. Analyzing the past to develop models may be able to inform the trajectory of infectious disease activity in the near-term future and allows for public health officials to consider real-world intervention strategies to help mitigate the spread of disease. References: Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Differential Effects of Intervention Timing on COVID-19 Spread in the United States
What do we know about immunity, the epidemiology, testing strategies, and data collection in the context of the coronavirus pandemic? On what basis are governments making decisions, and how much uncertainty is there in current epidemiological models? We answer these questions and more in the first episode of our new podcast series Science, Policy & Pandemics. In this week's episode, our host Rob Doubleday, sits down with infectious disease epidemiologist Professor James Wood and mathematician Professor Julia Gog to bring you an overview of infectious disease modeling and to answer some questions about the covid19 pandemic. This series on science, policy and pandemics is brought to you by the Centre for Science and Policy at the University of Cambridge, in partnership with Cambridge Infectious Diseases and the Cambridge Immunology Network. Our guests this week: Professor Julia Gog is a British mathematician, David N. Moore Fellow and Director of Studies in Mathematics at Queens' College, Cambridge and Professor of mathematical biology in the University of Cambridge Department of Applied Mathematics and Theoretical Physics. She is also a member of the Cambridge Immunology Network and the Cambridge Infectious Diseases Interdisciplinary Research Centre. She is a member of SPI-M. Professor James Wood is Head of Department of Veterinary Medicine and Alborada Professor of Equine and Farm Animal Science. He is a veterinary epidemiologist who specializes in emerging and zoonotic infectious diseases, with a focus on bat transmitted viruses in sub-Saharan Africa and bovine tuberculosis. -- This series is hosted by CSaP Executive Director Dr Rob Doubleday, and is edited and produced by CSaP Communications Coordinator Kate McNeil. If you have feedback about this episode, or questions you'd like us to address in a future week, please email enquiries@csap.cam.ac.uk .
Thomas Hartung, MD, Johns Hopkins Bloomberg School of Public Health, delivers an insightful overview of his work studying toxicity testing improvements, organoids, and advancing technologies. Dr. Hartung has departmental affiliations with the Environmental Health and Engineering and Molecular Microbiology and Immunology departments at Johns Hopkins. Dr. Hartung's work is heavily focused on creating a paradigm shift in toxicity testing to improve overall public health. Dr. Hartung has been an integral part of the implementation of the 2007 NRC vision document known as, “Toxicity Testing in the 21st Century – a vision and a strategy.” Dr. Hartung discusses his background, and the road he has taken to arrive at his current place as a leading voice in the discussions concerning toxicity and animal testing. He explains that the technological opportunities have advanced significantly in the last few years. Dr. Hartung discusses ‘organ on a chip' technologies and other advanced tissue, etc. work. As he explains, this field is permanently moving. The advancement of organoids, which are small, self-organized 3D tissue cultures that are actually derived from stem cells, is changing the way research is done. The research doctor talks about the importance of toxicity testing, cellular communication and tissue technology, as well as genomics and metabolomics, discussing nutrients, types of cells, and the coming research that will certainly advance the field. Learning from current experiences, he explains that the ‘human on a chip' technologies will continue to change as more research is done. Organoids are being used to test various compounds to observe the relative toxicity, but they are utilized for other reasons as well, such as modeling diseases. As Dr. Hartung states, the future will likely bring these types of systems into all kinds of toxicity testing, and replace animal testing altogether if possible.
Dr. James Hickman, Ph.D., and Chief Science Officer of Hesperos (hesperosinc.com), the ‘Human-on-a-Chip' company, delivers a thorough overview of his work designing custom systems for disease modeling and drug testing. Hickman is a pioneer in his field and noted for Hesperos' technological ‘Human-on-a-Chip' platform. Dr. Hickman is renowned for his work in general, and for publishing the very first serum-free, defined culture system specifically for neuronal systems (Schaffner, Barker, et al. 1995), which has now been extended from rat to mouse, and more recently—to human. Hickman is also recognized for his work that established functional in vitro systems. Dr. Hickman explains the origins of Hesperos. As the Ph.D. explains, he combined his technology… functional in vitro systems and his collaborator's multi-organ metabolic systems to create, as the old axiom states, an end result in which the whole is greater than the sum of its parts. This collaboration between Dr. Hickman and Michael L. Shuler, Ph.D. led to the beginning of Hesperos. Dr. Hickman explains functional readouts, and how they recreate functions such as muscle contractions, cardiac electrical activity, and force, neuronal communication, etc. and combine them into a multi-organ system where the fluid is recirculating. Dr. Hickman explains the Hesperos method and what they offer. Hesperos can provide four human-on-a-chip systems specifically designed for disease modeling and drug testing. And their multi-organ, human-based screening platforms are successful as a means to identify first-in-class drugs and develop unique medicines for complex diseases. The Ph.D. explains the differences between in vivo tissue engineering and in vitro tissue engineering in regard to reproducing function. Further, he discusses their hopes and expectations for approval to the clinical trial phase, for drugs that have been tested in the Hesperos systems. He talks about some of the FDA requirements for drugs, in regard to how the drugs work within systems, how long they stay active, etc. Dr. Hickman explains how the Hesperos system is especially great for difficult, rare diseases, as they can build a phenotypic model, produce aspects of the disease, and then demonstrate that the disease can be reversed or ameliorated. Wrapping up, Dr. Hickman talks about the specific types of models that their clients have requested. And as most of what Hesperos delivers is custom designed, there is a great scientific opportunity on the horizon.
Enhanced Audio PodcastAired date: 7/26/2010 3:00:00 PM Eastern Time
Enhanced Video PodcastAired date: 7/26/2010 3:00:00 PM Eastern Time
© 2020-2025 Ivy Podcast Discovery LLC
